NewsBenzingaHC Wainwright & Co. réitère son conseil d’achat sur Pyxis Oncology et maintient son objectif de cours à 8 $ HC Wainwright & Co. réitère son conseil d’achat sur Pyxis Oncology et maintient son objectif de cours à 8 $ Benzinga 2026.11.20 11:20 (GMT+0) Open on Benzinga Other news Symbotic Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58 HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $8 Price Target 'Andhra govt to tap nuclear power through SMR tech as alternative to thermal power' - Press Trust Of India Nvidia Stock Hits New 52-Week Low: Buy the Dip or Stay Away? Needham Downgrades BILL Holdings to Hold
Symbotic Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
'Andhra govt to tap nuclear power through SMR tech as alternative to thermal power' - Press Trust Of India